Newsroom
BioAge Labs, Inc. Faces Securities Fraud Lawsuits from Multiple Law Firms
By KlickAnalytics Data Insights | January 10, 2025 10:00AM ET
Key Points
- BioAge Labs, Inc. is facing a class-action lawsuit alleging false statements about the company's business and prospects, leading to inflated stock prices.
- Shareholders claim they were misled about the safety and prospects of a key drug candidate before the company's IPO last September.
- Multiple law firms, including Robbins Geller Rudman & Dowd LLP, Hagens Berman, Levi & Korsinsky, and Bronstein, Gewirtz & Grossman, LLC, have announced class action lawsuits against BioAge Labs, Inc.
- Investors who suffered losses on their BioAge Labs, Inc. investments are encouraged to contact the respective law firms before March 10, 2025, to discuss their rights.
- The lawsuits seek to recover damages for alleged violations of federal securities laws related to BioAge Labs, Inc.'s IPO.
Several law firms have initiated class-action lawsuits against BioAge Labs, Inc., a biopharmaceutical company focused on metabolic diseases. The lawsuits allege that the company made false statements regarding its business and prospects, causing its stock to trade at inflated prices. Shareholders claim they were misled about the safety and potential of a key drug candidate before BioAge's initial public offering (IPO) in September.
One of the law firms involved, Robbins Geller Rudman & Dowd LLP, has announced that investors who suffered substantial losses on their BioAge Labs, Inc. investments may have the opportunity to lead a class-action lawsuit. Similarly, Hagens Berman, Levi & Korsinsky, and Bronstein, Gewirtz & Grossman, LLC have also notified investors of their rights to participate in the lawsuits against BioAge Labs, Inc.
Investors who purchased BioAge shares in the company's IPO or on the open market and experienced significant losses are advised to reach out to the law firms before the deadline of March 10, 2025. The lawsuits aim to recover damages for alleged violations of federal securities laws in connection with BioAge Labs, Inc.'s IPO. If you suffered a loss on your BioAge Labs, Inc. investment and are seeking potential recovery under federal securities laws, contact the respective law firms for more information.
In the face of these allegations, BioAge Labs, Inc. is currently facing multiple lawsuits from different law firms, all seeking to hold the company accountable for its actions. Investors who believe they have been adversely affected by the alleged securities fraud committed by BioAge Labs, Inc. are urged to take action before the March 10, 2025 deadline to discuss their rights and potential for recovery.
For more information:
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with